Finally, MASTL protein overexpression in breast tumours was analysed in the Clinical Proteomic Tumour Analysis Consortium (CPTAC) and found to be highly significant for both reduced overall survival and poor progression free survival (Figure S1D). This evidence concerns the gene MASTL and neoplasm.